



Pierre Fabre

Please join us for one of our two symposia taking place on Friday 22nd October, 13:15–14:00



BRAFTOVI in combination with MEKTOVI is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF^{V600} mutation^{1,2}

Click [here](#) for BRAFTOVI® (encorafenib) + MEKTOVI (binimetinib) prescribing information




BRAFTOVI is indicated in combination with cetuximab, for the treatment of adult patients with mCRC with a BRAF^{V600E} mutation, who have received prior systemic therapy¹

Click [here](#) for BRAFTOVI® (encorafenib) prescribing information



Optimising future outcomes for the BRAF^{V600} mutant metastatic melanoma patient



BRAF^{V600E} early detection in patients with metastatic CRC: prognostic and therapeutic implications

Agenda (live)

13:15	Welcome and introduction (Chair)	Dr Pippa Corrie , Consultant Medical Oncologist, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust
13:17	Factors that impact clinical decision-making for management and treatment of patients with unresectable or metastatic BRAF ^{V600} melanoma	Dr Ashita Waterston , Consultant Medical Oncologist, The Beatson West of Scotland Cancer Centre, Glasgow
13:27	5-year COLUMBUS study data in the context of real-world treatment decisions	Dr Ricky Frazer , Consultant Medical Oncologist, Velindre Cancer Centre, Cardiff
13:52	Panel discussion and Q&A**	All
14:00	Symposium close	Dr Pippa Corrie

Agenda (pre-recorded* and live)

13:15	Welcome and introduction (Chair) (live)	Dr Michael Braun , Consultant Medical Oncologist, The Christie NHS Foundation Trust, Manchester
13:17	The importance of BRAF ^{V600E} testing for the mCRC patient population (Pre-recorded)	Dr Naureen Starling , Consultant Medical Oncologist, The Royal Marsden NHS Foundation Trust, London
13:27	Data from the BEACON CRC trial and implications for real-world clinical practice (Pre-recorded)	Dr Janet Graham , Consultant Medical Oncologist, The Beatson West of Scotland Cancer Centre, Glasgow
13:42	Real-world experience for BRAFTOVI® (encorafenib) + cetuximab use (Pre-recorded)	Dr Naureen Starling
13:52	Panel discussion and Q&A** (live)	All
14:00	Symposium close (live)	Dr Michael Braun

*Pre-recorded presentation videos prepared for and shown at recently-held Pierre Fabre CRC webinar on 28th September 2021.

**Please note that the speakers will only be able to address a selection of your on-licence questions. Questions may be submitted during the symposia.

BRAF, v-raf murine sarcoma viral oncogene homolog B1; **CRC**, colorectal cancer; **mCRC**, metastatic colorectal cancer.

1. Pierre Fabre Ltd. BRAFTOVI (encorafenib) Summary of Product Characteristics.

2. Pierre Fabre Ltd. MEKTOVI (binimetinib) Summary of Product Characteristics.

Pierre Fabre-marketed products will be discussed at these promotional symposia. These symposia are funded and organised by Pierre Fabre Limited and intended for healthcare professionals attending the Oncology Forum 2021 only. Any discussion on Pierre Fabre-marketed products will be restricted to the terms of the product licences. Healthcare professionals are recommended to consult the Summary of Product Characteristics at all times.

Adverse events should be reported. In the UK, reporting forms and information can be found at the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. In the Republic of Ireland adverse events should be reported to the HPR. Reporting information for the HPR can be found at: www.hpra.ie.

Adverse events should also be reported to Pierre Fabre Ltd. Telephone: United Kingdom 0800 0855 292, Republic of Ireland 1800 812 464; or email: uk_mi@pierre-fabre.com.

Medical information

For Pierre Fabre medical information enquiries, please telephone United Kingdom 0800 0855 292, Republic of Ireland 1800 812 464; or email: uk_mi@pierre-fabre.com.